CLDF Title
Home | Contact Us | Bookmark
HBV HE HCC HCV
About CLDF Centers of Educational Expertise  
CME Dinner Meetings Webcasts Slide Library Abstract Library Conference Highlights
 
Back  
 
Reuters Health Information (2010-07-08): Radioactive microspheres help some with colorectal cancer metastases

Clinical

Radioactive microspheres help some with colorectal cancer metastases

Last Updated: 2010-07-08 14:47:05 -0400 (Reuters Health)

NEW YORK (Reuters Health) - When metastatic colorectal cancer is confined to the liver, hepatic arterial injection of yttrium-90 resin microspheres can significantly improve response rates, Belgian researchers report.

Everyone in the trial had unresectable, treatment-refractory disease.

"This is the first randomized study showing that radio-embolization with yttrium-90-loaded microspheres for very selected patients with metastatic colorectal cancer limited to the liver and no other chemotherapy option, can induce a valuable benefit with few side effects," lead author Dr. Alain Hendlisz told Reuters Health by e-mail.

In a phase III trial reported online June 21st in the Journal of Clinical Oncology, Dr. Hendlisz of Institut Jules Bordet, Brussels, and colleagues randomized 46 patients to protracted fluorouracil infusion on days 1 through 14 every three weeks with or without hepatic intra-arterial injection of the microspheres. Forty-four were evaluable.

With a median follow-up of about 2 years, the median time to liver progression -- the primary endpoint -- was 5.5 months in the radio-embolization group compared to 2.1 months in the control group (p=0.003). Corresponding times to tumor progression (at any site) were 4.5 and 2.1 months (p=0.03).

Only one patient in the radio-embolization group experienced grade 3 or 4 toxicity, compared to six in the monotherapy group (p=0.10).

After progression, 35 patients received further treatment, including radio-embolization in 10 patients who had been assigned to the control group.

Median overall survival was 10.0 months in the microsphere group and 7.3 months in those initially randomized to monotherapy (p=0.80)

"This technique, which requires high (technical skill) and excellent work integration for oncologists, nuclear medicine specialists and radiologists, could have a great added value in future management of liver metastatic spread from colorectal cancer," Dr. Hendlisz said.

Earlier this year, a separate team of researchers reported using yttrium-90 in glass microspheres to treat patients with inoperable primary hepatocellular carcinoma. In some cases, they said, tumors could be shrunk to the point where patients could become eligible for liver transplantation. (See Reuters Health story of Mar 17, 2010.)

The current study was supported by Sirtex Medical Limited (Sydney, Australia) via provision of the yttrium-90 resin microspheres.

SOURCE: http://link.reuters.com/zap56m

J Clin Oncol 2010.

 
 
 
 
                 
 
HBV
Webcasts
Slide Library
Abstract Library
 
HE
CME Dinner Meeting
Webcasts
Slide Library
Abstract Library
 
HCC
Slide Library
Abstract Library
 
 
HCV
Webcasts
Slide Library
Abstract Library
 
CLDF Follow Us
   
 
About CLDF
Mission Statement
Board of Trustees
Board of Advisors
CLDF Supporters
 
Other Resources
Liver News Library
Journal Abstracts
Hep C Link to Care
 
Centers of
Educational Expertise
Regional Map
     
   
  The Chronic Liver Disease Foundation is a non-profit organization with content developed specifically for healthcare professionals.
© Copyright 2012-2014 Chronic Liver Disease Foundation. All rights reserved. This site is maintained as an educational resource for US healthcare providers only.
Use of this Web site is governed by the Chronic Liver Disease Foundation terms of use and privacy statement.